ASMQ

Cipla

Product category
  • 3-day cure, artemisinin-based combination therapy (artesunate-mefloquine)

Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg

Dosing
  • Once-daily for three days
Efficacy
  • 28 day PCR-corrected ACPR* 96.2%

Key features
  • Long post-treatment protection

  • Three-year shelf life

Challenges
  • Mefloquine API costs contribute to high price of finished product
  • Only one prequalified manufacturer
Status
  • Registered by Cipla in 10 countries
  • Prequalified in 2012
  • >1.3 million treatments distributed since 2012
  • Key role in areas of drug resistance containment in Greater Mekong Subregion
Previously
  • Developed by FACT Consortium (led by DNDi and TDR) with Farmanguinhos and transferred to Cipla for manufacture in Asia and to secure WHO prequalification in 2012. Incorporated into MMV portfolio in 2015

MMV Project Director
  • Adam Aspinall (ad interim)

* ACPR = adequate clinical and parasitological response